TY - JOUR
T1 - Universal Polymerase Chain Reaction Screening for Severe Acute Respiratory Syndrome Coronavirus 2 in Asymptomatic Patients Before Hospital Admission in Tokyo, Japan
AU - for the Keio Donner Project Team
AU - Uchida, Sho
AU - Uwamino, Yoshifumi
AU - Uno, Shunsuke
AU - Nagata, Mika
AU - Aoki, Wataru
AU - Murata, Mitsuru
AU - Kitagawa, Yuko
AU - Hasegawa, Naoki
N1 - Funding Information:
This research plan was reviewed and approved by the Keio University School of Medicine Ethics Committee (20200063). Individual informed consent was waived according to the national guidelines for retrospective studies. Sho Uchida designed the study, analyzed the data, and drafted the manuscript. Yoshifumi Uwamino, Shunsuke Uno, and Naoki Hasegawa designed the study and edited the manuscript. Mika Nagata and Wataru Aoki performed the PCR assays. Mitsuru Murata and Yuko Kitagawa conceptualized the study and revised the article for intellectual content. All authors contributed to writing the final manuscript. We thank the staff involved in the management of the in-hospital PCR center.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/9
Y1 - 2021/9
N2 - Objectives: Universal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; i.e., the causative agent of coronavirus disease 2019 [COVID-19]) polymerase chain reaction (PCR) screening before admission has been adopted by several hospitals to prevent nosocomial SARS-CoV-2 transmission from asymptomatic and pre-symptomatic patients. However, screening usefulness remains unclear because it depends on the regional COVID-19 prevalence, and only a few large-scale studies have been reported. Here we describe the universal PCR screening performed in our hospital before admission of more than 12,000 patients and their attendants to evaluate the usefulness of the screening. Methods: We retrospectively described the universal PCR screening results for asymptomatic patients and their attendants before planned admissions at a hospital in Tokyo, Japan, from August 3, 2020, through March 31, 2021. Nasopharyngeal swab samples were collected at an in-hospital PCR center. Results: In total, 12,133 persons (11,859 asymptomatic patients and 274 attendants) underwent PCR screening; nine (0.07%) tested positive for SARS-CoV-2 RNA. Conclusions: Universal PCR screening may be useful for the advanced detection of SARS-CoV-2 infected patients with or without symptoms, which can be a potential source of nosocomial SARS-CoV-2 transmission.
AB - Objectives: Universal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; i.e., the causative agent of coronavirus disease 2019 [COVID-19]) polymerase chain reaction (PCR) screening before admission has been adopted by several hospitals to prevent nosocomial SARS-CoV-2 transmission from asymptomatic and pre-symptomatic patients. However, screening usefulness remains unclear because it depends on the regional COVID-19 prevalence, and only a few large-scale studies have been reported. Here we describe the universal PCR screening performed in our hospital before admission of more than 12,000 patients and their attendants to evaluate the usefulness of the screening. Methods: We retrospectively described the universal PCR screening results for asymptomatic patients and their attendants before planned admissions at a hospital in Tokyo, Japan, from August 3, 2020, through March 31, 2021. Nasopharyngeal swab samples were collected at an in-hospital PCR center. Results: In total, 12,133 persons (11,859 asymptomatic patients and 274 attendants) underwent PCR screening; nine (0.07%) tested positive for SARS-CoV-2 RNA. Conclusions: Universal PCR screening may be useful for the advanced detection of SARS-CoV-2 infected patients with or without symptoms, which can be a potential source of nosocomial SARS-CoV-2 transmission.
KW - Covid-19
KW - Pcr
KW - Sars-cov-2
KW - Universal screening
UR - http://www.scopus.com/inward/record.url?scp=85111076365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111076365&partnerID=8YFLogxK
U2 - 10.1016/j.jcv.2021.104915
DO - 10.1016/j.jcv.2021.104915
M3 - Article
C2 - 34315009
AN - SCOPUS:85111076365
SN - 1386-6532
VL - 142
JO - Journal of Clinical Virology
JF - Journal of Clinical Virology
M1 - 104915
ER -